Introduction

Pancreatic cancer has been a difficult disease to move the needle on: median survival with first-line chemotherapy has hovered around six months for decades, and targeted therapy has largely unsuccess here despite working elsewhere. This year, that changed, with the first randomized phase 3 evidence that directly inhibiting mutant RAS extends survival, plus an early but genuinely exciting KRAS-targeted vaccine.

Why Pancreatic Cancer Has Been So Hard to Treat

Anatomically, the pancreas sits deep in the body surrounded by major vessels and digestive organs, making early detection and surgical resection difficult. Biologically, the disease is driven overwhelmingly by KRAS mutations, present in roughly 90 percent of cases, alongside a dense fibrotic stroma that impedes drug delivery. Early attempts at targeted therapy, including EGFR inhibition with erlotinib added to gemcitabine, produced only a modest survival improvement (6.4 versus 6.0 months) despite meeting statistical significance, a result that illustrates how little benefit even a "positive" pancreatic cancer trial has historically delivered in absolute terms.

Modern combination chemotherapy improved on this meaningfully: FOLFIRINOX-style regimens (oxaliplatin, irinotecan, 5-FU) and gemcitabine plus nab-paclitaxel both improved survival over gemcitabine alone (to roughly 9 to 11 months), and remain backbone first-line options. A less-discussed but genuinely important 2023 trial, NAPOLI-3, used liposomal irinotecan (which better penetrates the tumor's dense stroma) combined with oxaliplatin and 5-FU (NALIRIFOX) against gemcitabine plus nab-paclitaxel, and showed further improvement (progression-free survival 7.4 versus 5.6 months; overall survival improved as well, 11.1 months versus 9.2 months), establishing this liposomal-irinotecan-based regimen as another reasonable first-line option with a similar administration burden to standard FOLFIRINOX-based regimens.

Genetic testing remains essential for every pancreatic cancer patient at diagnosis: NTRK fusions, though rare, predict dramatic responses to TRK inhibitors; germline BRCA mutations (present in roughly 5 to 8 percent of patients) predict better response to platinum-based chemotherapy and identify candidates for maintenance PARP inhibition, which improves progression-free survival, though not yet overall survival, in this population.

RASolute 302: The First RAS-Targeted Therapy to Improve Survival in Pancreatic Cancer

KRAS had been considered essentially undruggable for decades: its binding pocket is shallow, its GTP-binding affinity is extremely high, and it constantly cycles between active and inactive states. The first breakthrough came with covalent inhibitors targeting the G12C mutation specifically, but G12C is rare in pancreatic cancer, where G12D and G12V  mutations are by far the most common alteration. Daraxonrasib is a newer, oral, non-covalent RAS(ON) inhibitor designed to work across multiple RAS mutation types (G12D, G12V, G12C, G13, Q61, and others) rather than being restricted to one specific mutation.

The phase 3 RASolute 302 trial tested daraxonrasib against investigator's choice of chemotherapy in about 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. The results, presented in the ASCO Plenary Session, were striking: median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, a hazard ratio of 0.40, nearly doubling survival in the second-line setting, with generally fewer serious adverse events than chemotherapy. This represents the first phase 3 evidence that directly targeting RAS improves survival in pancreatic cancer, and daraxonrasib may become a new standard second-line option once regulatory review is complete; the drug is not yet FDA-approved but has been granted Breakthrough Therapy and Orphan Drug designations, and an expanded-access program is available for appropriate patients now. A first-line trial testing daraxonrasib with or without chemotherapy is already underway with very encouraging preliminary data.

The most common side effects were dermatologic (rash) and gastrointestinal (mucositis, colitis), manageable with supportive care including prophylactic antibiotics and skin care, and generally less severe than what was seen with earlier, single-mutation-selective RAS inhibitors.

An Early KRAS Vaccine Shows a Genuine Survival Signal

Separately, a lymph-node-targeting KRAS peptide vaccine (using a lipid-linked amphiphile design to improve delivery to lymph nodes, where immune responses are generated) was tested in a phase 1 trial of 25 patients with resected pancreatic and colorectal cancer who had detectable minimal residual disease (via ctDNA or tumor markers) after standard locoregional treatment.

Patients who mounted a strong T-cell response to the vaccine (above a pre-specified threshold) had dramatically better outcomes than those who did not: relapse-free survival was not reached in strong responders versus about 3 months in weak responders, and overall survival was not reached versus about 16 months, both large, statistically significant differences despite the small sample size. This is very early, phase 1 data, but it is a genuinely encouraging signal that KRAS-targeted immunotherapy, not just small-molecule inhibition, may have a role in preventing recurrence after curative-intent treatment. Larger, randomized confirmation is needed before this changes practice.

For Patients

For patients with metastatic pancreatic cancer whose disease has progressed after first-line treatment, a new oral drug called daraxonrasib, which directly targets the mutated RAS protein driving most pancreatic cancers, nearly doubled survival compared with standard chemotherapy in a large randomized trial; it is not yet FDA-approved but is available now through an expanded-access program for eligible patients, and full approval is expected before too long. Every patient with pancreatic cancer should have their tumor tested for specific genetic markers (including MSI/MMR, HER-2 Ras, BRCA mutations and rarer fusion mutations) at diagnosis, since those findings alter effective meaningfully treatment changes. And for patients who have had surgery for pancreatic cancer, a KRAS-targeted vaccine is an early but promising area of research aimed at preventing the cancer from coming back, though it remains investigational.

Key Takeaways

  • The phase 3 RASolute 302 trial showed daraxonrasib, an oral RAS(ON) inhibitor active across multiple RAS mutation types, nearly doubles overall survival (13.2 vs 6.7 months) compared with chemotherapy in previously treated metastatic pancreatic cancer, the first RAS-targeted therapy to do so.

  • Daraxonrasib is not yet FDA-approved but is available through an expanded-access program (EAP) given its Breakthrough Therapy and Orphan Drug designations; a first-line trial is already underway.

  • Every pancreatic cancer patient should undergo genetic testing at diagnosis for Ras,, , MSI/MMR, HER-2, BRCA mutations, NTRK fusions, and other actionable alterations, since these findings change treatment selection and prognosis.

  • An early-phase KRAS-targeted vaccine showed a large difference in relapse-free and overall survival between strong and weak immune responders after curative-intent treatment, a promising but still investigational signal requiring larger confirmatory trials.

  • Combination chemotherapy (FOLFIRINOX-based or liposomal-irinotecan-based regimens- NALIRIFOX, or gemcitabine plus nab-paclitaxel) remains the backbone of first-line treatment for most patients, with genetic testing results informing further refinement.

References

  1. Wolpin BM, Musher BL, Manji GA, et al. Daraxonrasib as second-line treatment for metastatic pancreatic ductal adenocarcinoma (RASolute 302). Presented ASCO 2026 Plenary Session, Abstract LBA5; N Engl J Med. 2026.

  2. Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic adenocarcinoma (NAPOLI-3). Lancet. 2023.

  3. Pant S, et al. Lymph node-targeted, mutant KRAS-specific amphiphile vaccine (ELI-002 2P) in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat Med. 2025.